Novo Holdings A/S

Catalent Stockholders Approve Transaction with Novo Holdings

Retrieved on: 
水曜日, 5月 29, 2024
Biotechnology, Pharmaceutical, Health, Security (finance), Certification, Patient, Calendar, Novo, Special, CTLT, Novo Holdings A/S, CDMO

Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, today announced that, at its Special Meeting of Stockholders (the “Special Meeting”) held earlier today, its stockholders voted to approve the pending transaction under which Novo Holdings A/S (“Novo Holdings”) will acquire all outstanding shares of Catalent for $63.50 per share in cash (the “Merger”).

Key Points: 
  • Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, today announced that, at its Special Meeting of Stockholders (the “Special Meeting”) held earlier today, its stockholders voted to approve the pending transaction under which Novo Holdings A/S (“Novo Holdings”) will acquire all outstanding shares of Catalent for $63.50 per share in cash (the “Merger”).
  • “Today’s outcome represents an important milestone towards the closing of this transaction, and we thank our stockholders for their overwhelming support and their confidence in the future of Catalent,” said Alessandro Maselli, President and Chief Executive Officer of Catalent.
  • “Following the closing of the transaction, we look forward to writing the next chapter for Catalent, benefiting from Novo Holdings’ expertise and resources as we continue to be a global leading independent CDMO, developing, manufacturing and supplying products that help people live better and healthier lives.”
    Based on the preliminary count of the voting results from today’s Special Meeting, Catalent stockholders voted to approve the transaction with 99.2% of ballots cast in favor of the proposed transaction.
  • The transaction is expected to close towards the end of calendar year 2024, subject to customary closing conditions, including receipt of required regulatory approvals.

CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing

Retrieved on: 
火曜日, 5月 28, 2024
Security (finance), Patient, LP, Exchange, Investment, Jefferies, CD19, IND, Therapy, Sale, Cancer, Third Rock Ventures, BLA, Wellington Management Company, Novo Holdings A/S

SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $110.0 million, before deducting placement agent fees and other expenses.

Key Points: 
  • In the private placement, CARGO is selling 6,471,000 shares of its common stock, at a price of $17.00 per share.
  • The private placement is expected to close on May 30, 2024, subject to the satisfaction of customary closing conditions.
  • The private placement is being conducted in accordance with applicable Nasdaq rules and was priced to satisfy the “Minimum Price” requirement (as defined in the Nasdaq rules).
  • CARGO Therapeutics has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in the private placement.

Catalent, Inc. Reports Third Quarter Fiscal 2024 Results

Retrieved on: 
水曜日, 5月 8, 2024
Biotechnology, Pharmaceutical, Health, CTLT, Biopharmaceutical, GAAP, Novo Holdings A/S, Patient, Calendar, Growth, Pharma

Catalent, Inc. (NYSE: CTLT) (“Catalent”), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the third quarter of fiscal 2024, which ended March 31, 2024.

Key Points: 
  • Catalent, Inc. (NYSE: CTLT) (“Catalent”), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the third quarter of fiscal 2024, which ended March 31, 2024.
  • “I am pleased to report that in the fiscal third quarter Catalent returned to growth, including double-digit non-COVID year-on-year revenue growth.
  • Additionally, we achieved record third quarter non-COVID customer wins, and our non-COVID customer wins in the first three quarters of the fiscal year increased double digits over the prior year.
  • Third quarter fiscal 2024 Adjusted EBITDA(1) was $163 million, or 15.1% of net revenue, compared to $105 million, or 10.1% of net revenue, in the third quarter a year ago.

Healthcare M&A Volume Falls in Q1:24, According to Acquisition Data from LevinPro HC

Retrieved on: 
金曜日, 4月 12, 2024
Housing, Laboratory, Novo Holdings A/S, Research, EHealth, Intelligence, CDMO, Catalent, Biotechnology, HC, Acquisition, Medicare, MRI, Hospice, Novo Nordisk Foundation, Dialysis, Pharmaceutical industry

NEW CANAAN, Conn., April 12, 2024 /PRNewswire-PRWeb/ --  Healthcare merger and acquisition activity declined by 4% in the first quarter of 2024, according to new acquisition data from LevinPro HC. Deal volume in Q1:24 only reached 494 deals, falling short of the 515 transactions announced in the fourth quarter of 2023. Year-over-year changes were even more pronounced, with an 11% decline in activity in Q1:24 compared with the first quarter of 2023, when 555 deals were announced.

Key Points: 
  • Healthcare merger and acquisition activity declined by 4% in the first quarter of 2024, according to new acquisition data from LevinPro HC.
  • Deal volume in Q1:24 only reached 494 deals, falling short of the 515 transactions announced in the fourth quarter of 2023.
  • NEW CANAAN, Conn., April 12, 2024 /PRNewswire-PRWeb/ --  Healthcare merger and acquisition activity declined by 4% in the first quarter of 2024, according to new acquisition data from LevinPro HC.
  • Deal volume in Q1:24 only reached 494 deals, falling short of the 515 transactions announced in the fourth quarter of 2023.

Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing

Retrieved on: 
水曜日, 3月 13, 2024
SVB Securities, Stifel, Common stock, Novo Holdings A/S, Sale, Public expenditure, Prospectus, Therapy, Security (finance)

Lexeo sold 6,278,905 shares of its common stock (“Common Stock”) in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), at a sale price equal to $15.13 per share.

Key Points: 
  • Lexeo sold 6,278,905 shares of its common stock (“Common Stock”) in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), at a sale price equal to $15.13 per share.
  • Lexeo intends to use net proceeds from the financing to fund advancement of ongoing clinical stage programs, and for working capital and general corporate purposes.
  • The proceeds from this financing, combined with current cash, cash equivalents and marketable securities, are expected to fund operating and capital expenditures into 2027.
  • Any offering of the shares sold in the private placement under the Resale Registration Statement will only be made by means of a prospectus.

Obsidian Therapeutics Announces Oversubscribed $160.5 Million Series C Financing to Drive OBX-115 Clinical Development

Retrieved on: 
水曜日, 4月 3, 2024
Biotechnology, Health, Genetics, Clinical Trials, Oncology, Janus, Growth, Novo Holdings A/S, NSCLC, TIL, Patient, Wellington Management Company, Paradigm, Foresite Capital, Bristol Myers Squibb, Lung cancer, Doctor of Philosophy, Therapy, Melanoma, Investment, Atlas Venture, Pharmaceutical industry

Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a significantly oversubscribed $160.5 million Series C financing with a top-tier syndicate of life science investors led by new investor, Wellington Management.

Key Points: 
  • Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a significantly oversubscribed $160.5 million Series C financing with a top-tier syndicate of life science investors led by new investor, Wellington Management.
  • Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC).
  • The Company is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.
  • “This financing provides funding through key clinical readouts in melanoma and is the catalyst to continue expanding OBX-115 into NSCLC, where there is significant potential and high unmet need.”

Trinity Hunt Announces Formation of Supreme Group and Appoints Tom Donnelly CEO

Retrieved on: 
水曜日, 3月 20, 2024
Professional Services, Marketing, Health, Digital Marketing, Communications, Finance, General Health, Knowledge, MKG, Growth, Medicine, Court Square Capital Partners, Novo Holdings A/S, Donnelly (surname), Evoke, Advertising, Pharmaceutical industry

Supreme Group was formed following Trinity Hunt Partners ’ majority investment in Supreme Optimization , a leading life science-focused digital agency providing best-in-class performance digital marketing services to the life science industry.

Key Points: 
  • Supreme Group was formed following Trinity Hunt Partners ’ majority investment in Supreme Optimization , a leading life science-focused digital agency providing best-in-class performance digital marketing services to the life science industry.
  • “Tom’s extensive experience leading and growing healthcare marketing and communications businesses makes him the ideal leader for Supreme Group,” said Mike Steindorf, partner at Trinity Hunt.
  • “I am excited to join Supreme Group and look forward to making an impact in this dynamic and growing space,” said Donnelly.
  • “Already during my short time working with Trinity Hunt and the team at Supreme Optimization, we have made tremendous progress in building the Supreme Group platform.”

Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing

Retrieved on: 
月曜日, 3月 11, 2024
Prospectus, Novo Holdings A/S, Stifel, J. P. Morgan, Common stock, Sale, SVB Securities, Therapy, Public expenditure, Security (finance)

Lexeo anticipates the gross proceeds from the private placement to be approximately $95.0 million, before deducting any offering related expenses.

Key Points: 
  • Lexeo anticipates the gross proceeds from the private placement to be approximately $95.0 million, before deducting any offering related expenses.
  • The financing is expected to close on March 13, 2024, subject to customary closing conditions.
  • Lexeo intends to use net proceeds from the financing to fund advancement of ongoing clinical stage programs, and for working capital and general corporate purposes.
  • The proceeds from this financing, combined with current cash, cash equivalents and marketable securities are expected to fund Lexeo’s operating and capital expenditures into 2027.

Novo Nordisk Foundation awarded more than DKK 9.1 billion for purposes benefitting society in 2023

Retrieved on: 
水曜日, 3月 6, 2024
Novo Nordisk Foundation, Research, Biotechnology, DKK, Antimalarial medication, Education, Investment, Food, Partnership, NIVI, Vaccine, University, Health, Climate change, Novo Holdings A/S, CO2, Protein, Tuberculosis, Science, Agriculture, Bill, Human

In 2023, the Foundation awarded more than DKK 9.1 billion, in philanthropic grants and investments, and supported a total of 751 new projects.

Key Points: 
  • In 2023, the Foundation awarded more than DKK 9.1 billion, in philanthropic grants and investments, and supported a total of 751 new projects.
  • One of its largest mission-driven initiatives in 2023 was the Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI), a research and vaccine development initiative launched in partnership with the University of Copenhagen.
  • The DKK 9.1 billion awarded in 2023 marks an increase in grant giving from previous years.
  • The Novo Nordisk Foundation Cellerator, a world-class facility for developing and upscaling cell therapies for testing in humans.

Novo Nordisk Foundation awarded more than DKK 9.1 billion for purposes benefitting society in 2023

Retrieved on: 
水曜日, 3月 6, 2024
Novo Nordisk Foundation, Research, Biotechnology, DKK, Antimalarial medication, Education, Investment, Food, Partnership, NIVI, Vaccine, University, Health, Climate change, Novo Holdings A/S, CO2, Protein, Tuberculosis, Science, Agriculture, Bill, Human

In 2023, the Foundation awarded more than DKK 9.1 billion, in philanthropic grants and investments, and supported a total of 751 new projects.

Key Points: 
  • In 2023, the Foundation awarded more than DKK 9.1 billion, in philanthropic grants and investments, and supported a total of 751 new projects.
  • One of its largest mission-driven initiatives in 2023 was the Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI), a research and vaccine development initiative launched in partnership with the University of Copenhagen.
  • The DKK 9.1 billion awarded in 2023 marks an increase in grant giving from previous years.
  • The Novo Nordisk Foundation Cellerator, a world-class facility for developing and upscaling cell therapies for testing in humans.